Clinical trials: Chronic Hepatitis B Infections
Chronic Hepatitis B
Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection
Entecavir(ETV) plus Tenofovir Disoproxil Fumarate(TDF) combination will show effective antiviral activity and prevent further development of antiviral resistance in hepatitis B e antigen(HBeAg)-positive or -negative Chronic…
- Trial name
- NCT01594905
- Testing
- Entecavir + Tenofovir (MDR group)
- Volunteers
- 90 people
- Sponsor
- Yonsei University
Chronic HBV Infection
Methylene Blue Treatment of Chronic Hepatitis B Virus Infection
HBV infection is a global public health problem. It is estimated that there are more than 250 million HBV carriers worldwide, of whom approximately 600,000 die each year from HBV-related liver disease.
- Trial name
- MB_HBV (NCT06887036)
- Testing
- Methylene Blue
- Where
- Switzerland
- Volunteers
- 10 people
- Sponsor
- Fondazione Epatocentro Ticino
Liver Failure, Acute on Chronic, Liver Injury
A Retrospective Multicenter Study of HBV-related Pre-acute-on-chronic Liver Failure in China
The definition and diagnostic criteria of Acute-on-chronic liver failure (ACLF) has been well established by EASL CANONIC study. However, patients with high risk to develop ACLF has not been determined, yet.
- Trial name
- NCT03281265
- Testing
- standard treatment
- Volunteers
- 1,178 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hepatitis B, Chronic
An Observational Study in Participants With Chronic Hepatitis B (CHB) Receiving Therapy With Peginterferon Alfa-2a 40 Kilodaltons (kD) (PEGASYS) - The PRO B Study
This open--label, multicenter, national observational study will investigate the effectiveness of standard of care treatment with peginterferon alfa-2a in participants with chronic hepatitis B (CHB).
- Trial name
- NCT02201407
- Testing
- Peginterferon alfa-2a
- Where
- 6 sites in Serbia
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis B
A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs
This is a randomized, open-label, multicenter phase II study to evaluate the efficacy and safety of AHB-137 injection in combination with other hepatitis B drugs in participants with HBeAg-negative CHB treated with NAs.
- Trial name
- NCT07069569
- Testing
- AHB-137, Peg-IFN, Hepatitis B Vaccine
- Where
- 14 sites in China
- Volunteers
- 200 people
- Sponsor
- Ausper Biopharma Co., Ltd.
Hepatitis B, Chronic
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B
This 3 arm study will assess the efficacy and safety of PEGASYS alone, or in combination with Adefovir or Entecavir in patients with HBeAg positive chronic hepatitis B.
- Trial name
- NCT00922207
- Testing
- Adefovir, Entecavir, peginterferon alfa-2a [Pegasys]
- Where
- 9 sites in Taiwan
- Volunteers
- 280 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C
A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection
A phase 3 Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of the combined single dose of Dactavira Plus (EPGCG, Sofosbuvir , Daclatasvir \& Ribavirin) versus Sofosbuvir + Daclatasvir + Ribavirin (Part A) and a…
- Trial name
- NCT03186313
- Testing
- Dactavira Plus, Sofosbuvir + Daclatasvir + Ribavirin, Dactavira
- Where
- Egypt
- Volunteers
- 72 people
- Sponsor
- Egyptian Liver Hospital
Chronic Hepatitis B
Immune Function Status and the Prevalence of Hepatitis in Postpartum Pregnant Women With CHB Infection
To date, several studies have manifested that high levels of adrenal corticosteroids and oestrogen hormones during pregnancy can lead to increased HBV viraemia.
- Trial name
- NCT02886182
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Beijing Ditan Hospital
Hepatitis B, Chronic
A Study of Peginterferon Alfa-2a (Pegasys) in Participants With Hepatitis B E-Antigen (HBeAg)-Positive Chronic Hepatitis B Virus (HBV)
This is a study of the efficacy and safety of peginterferon alfa-2a (Pegasys) in naive, interferon- or lamivudine-pretreated participants with HBeAg-positive chronic HBV.
- Trial name
- NCT02604823
- Testing
- Peginterferon alfa-2a
- Where
- 3 sites in China
- Volunteers
- 307 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis B
Long Term Follow-up of Pegylated-Interferon Alpha-2b
The aim of this study was to investigate the long term outcome of Peginterferon alpha-2b with or without the addition of lamivudine in patients with chronic hepatitis B
- Trial name
- NCT00146705
- Testing
- blood samples are taken once
- Where
- Netherlands
- Volunteers
- 266 people
- Sponsor
- Foundation for Liver Research
Chronic Hepatitis B Infection
Cohort Study of Clinical Outcomes in Chronic HBV Infection Patients With Low HBsAg Under Unplanned Intervention
All chronic hepatitis B (CHB) patients were diagnosed and treated in the liver disease department of the Hepatology Center of Beijing Ditan Hospital affiliated to Capital Medical University and those who received antiviral…
- Trial name
- NCT04030039
- Testing
- Interferon, nucleoside analogues
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Beijing Ditan Hospital
Chronic Hepatitis B
A Study to Evaluate the Mass Balance Absorption and AME of VBR
This Phase 1 Study will determine the mass balance recovery, absorption, metabolism, and excretion of [14C] Vebicorvir in healthy male subjects
- Trial name
- NCT04637139
- Testing
- Vebicorvir (VBR)
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Assembly Biosciences
Chronic Hepatitis B
Sequential Combination Therapy With PD-1 Antibody and Peg-IFNα in CHB Patients
This is a prospective study to evaluate the safety and efficacy of Sintilimab (PD-1 antibody) in sequential combination with Peg-IFNα-2b in NA-supressed CHB patients who had previously received Peg-IFNα therapy.
- Trial name
- NCT06457477
- Testing
- Sintilimab, NAs, Peg-IFNα-2b
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Beijing 302 Hospital
Chronic HBV Infection (HBeAg Negative)
REP 2139-Ca / Pegasys™ Combination Therapy in Hepatitis B / Hepatitis D Co-infection
REP 2139-Ca is nucleic acid polymer. Nucleic acid polymers have been previously shown to clear serum hepatitis B virus surface antigen (HBsAg) both preclinically (in duck HBV infected ducks) and in human patients and to act…
- Trial name
- NCT02233075
- Testing
- REP 2139-Ca + Pegasys (TM)
- Where
- Moldova
- Volunteers
- 12 people
- Sponsor
- Replicor Inc.
Chronic Hepatitis B
An Open Study to Evaluate the Efficacy, Safety of Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis B
This is an open study to evaluate the efficacy, safety of clevudine monotherapy or adefovir and clevudine combination in patients with chronic hepatitis B.
- Trial name
- NCT01264354
- Testing
- Clevudine 30mg, Clevudine 20mg+Adefovir dipivoxil 10mg, Clevudine 20mg
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Bukwang Pharmaceutical
Hepatitis B, Chronic
Persistence, Adherence and Clinical Effectiveness of Entecavir in Chronic Hepatitis B Patients
The purpose of this observational study is to measure the real-life persistence, adherence and clinical effectiveness of entecavir in patients with chronic Hepatitis B viral infection.
- Trial name
- NCT01356901
- Where
- Germany
- Volunteers
- 230 people
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis B
A Study to Compare and Evaluate Intrahepatic cccDNA Reduction After Administrating Clevudine or Entecavir in the Chronic HBV Patients
This is a open, randomized, parallel study. Subjects will have Clevudine or Entecavir therapy for 48 weeks(Clevudine:Entecavir = 2:1), and subjects who have Complete Response(HBV DNA negative and ALT normal) will have follow-up…
- Trial name
- NCT01266005
- Testing
- Clevudine, Entecavir
- Where
- South Korea
- Volunteers
- 75 people
- Sponsor
- Bukwang Pharmaceutical
Hepatitis B
Follow-up of HBsAg Inactive Carriers Study
The definition of HBs antigen (HBsAg) inactive carrier status has evolved during time. We spoke first from HBsAg" healthy carrier ", then from " asymptomatic carrier ", last from HBsAg" inactive carrier ".
- Trial name
- PIBAC (NCT02247752)
- Testing
- inactive carrier
- Where
- 32 sites in France
- Volunteers
- 619 people
- Sponsor
- Centre Hospitalier Régional d'Orléans
Hepatitis B, Chronic
A Single-arm Study Evaluating the Efficacy and Safety of Telbivudine With or Without add-on Tenofovir in Adults With HBeAg-positive Chronic Hepatitis B (CHB)
This study will evaluate the use of telbivudine for patients with HBeAg-positive CHB with an option to intensify treatment at Week 24 by adding tenofovir for patients who do not achieve HBV DNA non-detectability.
- Trial name
- NCT00651209
- Testing
- Tenofovir
- Where
- 4 sites in Argentina, Brazil and 2 more
- Volunteers
- 105 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Hepatitis B
A Clinical Trial to Evaluate the Efficacy and Safety of TQA3810 Tablets in Combination/Non Combination With Nucleoside (Acid) Analogues in Patients With Primary/Treated Chronic Hepatitis B
To evaluate the efficacy and safety of combined/uncombined nucleoside (acid) analogues of TQA3810 tablets.
- Trial name
- NCT06566248
- Testing
- TQA3810 tablets+NUC
- Where
- 6 sites in China
- Volunteers
- 90 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.